As the year comes to a close, the Office of Communications is rerunning some of the biggest and most read stories posted in 2022, with topics such as the UMass Chan research that guided the FDA on recommendations for rapid COVID-19 tests, plans for a regional medical campus with Lahey Hospital & Medical Center in Burlington and The Boston Globe’s Top Places to Work list, which included UMass Chan for the first time. Look for these stories on UMass Chan News between Dec. 21 and Dec. 30. This story was originally published on Aug. 11.
Findings from a new study led by UMass Chan Medical School researchers are the basis for a safety communication issued by the U.S. Food and Drug Administration (FDA) Aug. 11 regarding serial use of at-home antigen tests for COVID-19.
The study results show that at-home antigen tests are more likely to detect COVID-19 within the first week of infection when a person without symptoms tests three times, at 48-hour intervals, and a person with symptoms tests twice, according to the study by UMass Chan researchers and partners supported by the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Tech program. The research appeared in medRxiv, a preprint online platform, and has not yet been peer reviewed.
This study is a culmination of close collaboration with the FDA and NIH. The UMass Chan team has been working for the past year to ensure that the best evidence was generated for performance of rapid antigen tests in asymptomatic people, according to Apurv Soni, MD, PhD’21, assistant professor of medicine and principal investigator on the study.
The FDA’s safety communication recommends people perform repeat, or serial, testing following a negative result on any at-home COVID-19 antigen test. If repeat testing is not performed after a negative result, an infection may be missed and people may unknowingly spread the SARS-CoV-2 virus to others, especially if they are not experiencing symptoms. The FDA recommends repeat testing following a negative result whether or not a person has COVID-19 symptoms.
“To our knowledge, this is one of the largest studies to date that examined COVID-19 rapid antigen test performance serially over two weeks. The results of this study show that rapid tests detect the omicron as well as delta variants and that serial testing with antigen tests remains a useful way to detect infection,” said co-author Nathaniel Hafer, PhD, assistant professor of molecular medicine and lead investigator of the RADx Tech Clinical Studies Core Logistics Team.
The study analysis looked at 5,609 eligible people over age 2 across the country, from among 7,361 who were enrolled in the national Test Us At Home study, conducted by the RADx Tech Clinical Studies Core between October 2021 and January 2022. Participants took an at-home antigen test using one of three retail test kits, which are available in the United States, and collected a sample for a molecular PCR test, using nasal swabs for both types of test samples. They tested themselves every 48 hours for 15 days.
During the test period, 154 participants tested positive for SARS-CoV-2 infection based on molecular PCR assays.
Serial testing with an at-home antigen test twice over 48 hours resulted in detection of more than 90 percent of infections when symptomatic people started testing within the first week of infection, the study reports.
Among those who did not have symptoms but had an infection lasting at least two days based on PCR testing, serial testing three times with an at-home antigen test at 48-hour intervals detected more than 75 percent of infections, an increase from roughly 60 percent sensitivity after testing just twice.
An implication of findings from this study is that people who are suspected to be infected with the SARS-CoV-2 virus but have not developed symptoms should exercise caution, such as wearing masks and avoiding crowded places, for at least six days until three at-home antigen tests taken 48 hours apart have been performed, according to the study’s authors.
Dr. Hafer added that this large-scale study was made possible by its novel app-based digital enrollment and reporting features, developed by the UMass Chan Program in Digital Medicine, which is a much more streamlined method compared with traditional interventions in clinical trials. “This study demonstrates that it’s possible to rapidly enroll and conduct clinical research with digital techniques,” he said. “We feel that our participants had a pretty seamless experience. However, this was the result of a tremendous amount of work and coordination by our study team and our partners such as Quest Diagnostics, CareEvolution, community health centers and rapid test manufacturers.”
The research was funded by the NIH RADx Tech program, administered by the National Institute of Biomedical Imaging and Bioengineering.
Related UMass Chan news stories:
What’s the difference between a PCR and antigen COVID-19 test?
RADx Tech program researchers ramp up rapid home COVID-19 test studies
UMass Medical School helps lead NIH RADx to accelerate new COVID test technologies
